1. Home
  2. PZZA vs CGEM Comparison

PZZA vs CGEM Comparison

Compare PZZA & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Papa John's International Inc.

PZZA

Papa John's International Inc.

HOLD

Current Price

$35.80

Market Cap

1.2B

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$17.62

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PZZA
CGEM
Founded
1984
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
PZZA
CGEM
Price
$35.80
$17.62
Analyst Decision
Buy
Strong Buy
Analyst Count
8
8
Target Price
$45.00
$30.13
AVG Volume (30 Days)
946.4K
1.4M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
5.25%
N/A
EPS Growth
N/A
N/A
EPS
0.21
N/A
Revenue
$2,068,421,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.20
P/E Ratio
$170.57
N/A
Revenue Growth
14.07
N/A
52 Week Low
$30.16
$5.68
52 Week High
$55.74
$19.43

Technical Indicators

Market Signals
Indicator
PZZA
CGEM
Relative Strength Index (RSI) 55.53 61.58
Support Level $35.50 $11.87
Resistance Level $39.37 N/A
Average True Range (ATR) 1.65 1.18
MACD 0.21 0.25
Stochastic Oscillator 64.35 72.89

Price Performance

Historical Comparison
PZZA
CGEM

About PZZA Papa John's International Inc.

Papa John's International Inc operates and franchises pizza delivery and carryout restaurants and, in certain international markets, dine-in and delivery restaurants. It has four defined reportable segments: Domestic Company-owned restaurants, North America franchising, North America commissaries, and International. The company derives maximum revenue from North America commissaries segment. The North America commissaries segment consists of the operations of its regional dough production and product distribution centers in the United States and Canada and derives its revenues principally from the sale and distribution of food and paper products to Domestic Company-owned and franchised restaurants in the United States and Canada.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: